Key facts
- It has raised $1.4M across 1 recorded rounds; the latest was Seed Round ($1.4M) in Feb 2026.
- AminoSense has filed 1 Form D with the SEC, most recently Mar 2026 ($1.4M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for AminoSense
Funding rounds
1 roundsAbout AminoSense
Developer of amino acid-based health and wellness products designed to enhance human health, support metabolic function, and improve overall quality of life. The company offers biotechnology services while developing amino acid-based health products through biochemical research, enabling clients to support metabolic, cognitive, and physical health. scientific research and rigorous quality standards with cognitive functions and physical performance in a safe, effective, and evidence-based formulation.
- Sector
- Healthcare
- HQ
- Montclair, NJ, United States
- Founded
- 2023
- Ownership
- Privately Held (backing)
AminoSense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AminoSense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AminoSense in its N-PORT filings yet. We sweep new filings monthly.